The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,101–2,200 of 4,628
Gao, F., You, X., Yang, L., Zou, X., & Sui, B. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2333275 · Cited by 15
Singh, S., & Wairkar, S. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02793-y · Cited by 14
Tokhanbigli, S., Haghi, M., Dua, K., & Oliver, B. G. G. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.55 · Cited by 24
Cepharanthine attenuates pulmonary fibrosis via modulating macrophage M2 polarization
Bao, J., Liu, C. X., Song, H., Mao, Z., Qu, W., Yu, F., Shen, Y., Jiang, J., Chen, X., Wang, R., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03250-z · Cited by 14
Boateng, E., Bonilla-Martinez, R., Ahlemeyer, B., Garikapati, V., Alam, M. R., Trompak, O., Oruqaj, G., El-Merhie, N., Seimetz, M., Ruppert, C., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02935-7 · Cited by 18
Maetani, T., Tanabe, N., Tanizawa, K., Sakamoto, R., Shiraishi, Y., Hayashi, Y., Uyama, M., Matsunashi, A., Satô, S., Suzuki, K., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-03032-5 · Cited by 13
Mitochondrial Transplantation Ameliorates Pulmonary Fibrosis by Suppressing Myofibroblast Activation
Lee, S.-E., Yu, S.-H., Kim, I.-H., Kang, Y. C., Kim, Y., Yeo, J. S., Lim, J., Kwon, I., Kim, J.-H., Park, S.-W., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312783 · Cited by 17
“Two approved anti-fibrotic drugs, namely pirfenidone and nintedanib, have slowed disease progression and increased the length of life for patients with IPF [2,3].”
Inoue, Y., Ogura, T., Azuma, A., Kondoh, Y., Homma, S. A., Muraishi, K., Ikeda, R., Ochiai, K., Sugiyama, Y., & Nukiwa, T. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03079-2 · Cited by 18
Self-citationYu, Y., Macaulay, D. S., Reichmann, W. M., Wu, E. Q., & Nathan, S. D. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.11.001 · Cited by 13
“Consequently, the rates of suspected AEx-IPF observed in this study may be higher than the AEx-IPF rates in clinical trial and observational studies that use more stringent criteria [1,7,14].”
ResultO’Donnell, D. E., Neder, J. A., Harle, I. A., & Moran‐Mendoza, O. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1251843 · Cited by 14
Existing and emerging treatments for idiopathic pulmonary fibrosis
Kolilekas, L., Papiris, S. A., & Bouros, D. E. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1568244 · Cited by 15
“those who have coronary artery disease [20,37].”
BackgroundInfluentialMetabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics
Zhou, Z., Wang, Y., Yan, D.-M., Fang, J.-H., Xiao, X.-R., Zhang, T., Cheng, Y., Xu, K.-P., & Li, F. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.113045 · Cited by 14
Vacchi, C., Manfredi, A., Cassone, G., Salvarani, C., Cerri, S., & Sebastiani, M. (2020) · Case Reports in Medicine · doi:10.1155/2020/6390749 · Cited by 14
Aschner, Y., Nelson, M., Brenner, M., Roybal, H. M., Beke, K. M., Meador, C., Foster, D. G., Correll, K. A., Reynolds, P. R., Anderson, K. C., et al. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00235.2019 · Cited by 15
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities
Cruwys, S., Hein, P., Humphries, B., & Black, D. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.019 · Cited by 15
Kim, J. W., Barrett, K., Loke, Y. K., & Wilson, A. M. (2020) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100792 · Cited by 14
Kanaji, N., Shimizu, J., Sakai, K., Ueda, Y., Miyawaki, H., Watanabe, N., Uemura, T., Hida, T., Inoue, T., Watanabe, N., et al. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620963866 · Cited by 13
Functional parameters of small airways can guide bronchodilator use in idiopathic pulmonary fibrosis
Hu, P., Ko, H., Su, K., Feng, J., Su, W., Hsiao, Y., & Perng, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-75597-2 · Cited by 13
Fu, J., Lü, L., Wang, H., Hou, Y., & Dou, H. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51654 · Cited by 13
3-Carbamoyl-proxyl nitroxide radicals attenuate bleomycin-induced pulmonary fibrosis in mice
Assayag, M., Goldstein, S., Samuni, A., & Berkman, N. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.010 · Cited by 13
Nintedanib-Induced Renal Thrombotic Microangiopathy
Fujita, T., Nakagawa, H., Yokota, T., et al. (2021) · Case Reports in Nephrology and Dialysis · doi:10.1159/000517692 · Cited by 13
Diagnosis Yield and Safety of Surgical Biopsy in Interstitial Lung Diseases: A Prospective Study
Radu, D. M., Freynet, O., Kambouchner, M., Boubaya, M., Nunès, H., Uzunhan, Y., Brillet, P., Guiraudet, P., Noorah, M. Z., Israël‐Biet, D., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.08.056 · Cited by 14
Case Report: Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019
Bussolari, C., Palumbo, D., Fominskiy, E. V., Nardelli, P., LORENZO, R. D., Vitali, G., COBELLI, F. D., Rovere, P. Q., & Scandroglio, A. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.766486 · Cited by 13
“Nintedanib is approved in patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs), due to its proven beneficial effects on the rate of lung function decline and thus on disease progression (10).”
Backgroundvan Leeuwen, L. L., Leuvenink, H. G. D., Olinga, P., & Ruigrok, M. J. R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806774 · Cited by 13
Yao, Y., Li, Z., & Gao, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.855789 · Cited by 15
Zheng, J., Dong, H., Zhang, T., Ning, J., Xu, Y., & Cai, C. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.865052 · Cited by 17
“Currently, there are only two FDA-approved drugs for IPF (pirfenidone and nindanib), which do not prevent or reverse the progression of the disease or reduce mortality; they can only moderately reduce the rate of deterioration of lung function (King et al., 2014; Richeldi et al., 2014).”
BackgroundStandardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
Tanaka, Y., Suzuki, Y., Hasegawa, H., Yokomura, K., Fukada, A., Inoue, Y., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02062-1 · Cited by 14
Self-citationPhysiotherapy management of interstitial lung disease
Holland, A. E. (2022) · Journal of physiotherapy · doi:10.1016/j.jphys.2022.06.006 · Cited by 15
Kagawa, K., Sato, S., Koyama, K., Imakura, T., Murakami, K., Yamashita, Y., Naito, N., Ogawa, H., Kawano, H., & Nishioka, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275987 · Cited by 14
Miao, Y., Li, X., Yang, Y., Zhang, J., Chen, L., Zhang, Q., Li, W., Liu, Y., Zhang, X., Gu, R., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109427 · Cited by 17
Diagnosing lung involvement in inflammatory rheumatic diseases—Where do we currently stand?
Hoffmann, T., Oelzner, P., Teichgräber, U. K.-M., Franz, M., Gaßler, N., Kroegel, C., Wolf, G., & Pfeil, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1101448 · Cited by 14
“FVC is widely used as primary endpoint in studies, but is also a generally recognized sign of disease progression (decline of 10%) (21, 58, 59).”
BackgroundMethodNICE guidance on nintedanib for treating idiopathic pulmonary fibrosis
Laurenson, S. X., Sidhu, R., Goodall, M., & Adler, A. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00022-9 · Cited by 13
Avdeev, S. N. (2015) · PULMONOLOGIYA · doi:10.18093/0869-0189-2015-25-5-600-612 · Cited by 15
Nintedanib in Advanced NSCLC: Management of Adverse Events
Lemmens, L. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.33 · Cited by 15
Great expectations for simtuzumab in IPF fall short
Meyer, K. C. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30420-9 · Cited by 14
Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis
Nambiar, A. M., Anzueto, A., & Peters, J. I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176312 · Cited by 13
Recent progress in systemic sclerosis-interstitial lung disease
Castelino, F. V., & Dellaripa, P. F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000544 · Cited by 13
Oishi, K., Hirano, T., Murata, Y., Hamada, K., Uehara, S., Suetake, R., Yamaji, Y., Asami‐Noyama, M., Edakuni, N., Ohata, S., et al. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619872890 · Cited by 16
Dabo, A. J., Ezegbunam, W., Wyman, A. E., Moon, J., Railwah, C., Lora, A., Majka, S. M., Geraghty, P. M., & Foronjy, R. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0177oc · Cited by 13
“Inhibitors for c-Src have been investigated for lung cancer (49) and idiopathic pulmonary fibrosis (50), but not for COPD.”
BackgroundJones, I. C., Espíndola, M. S., Narayanan, R., Coelho, A. L., Habiel, D. M., Boehme, S. A., Ly, T. W., Bacon, K. B., & Hogaboam, C. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56393-z · Cited by 13
Lu, F., Sun, X., Xu, X., & Jiang, X. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114916 · Cited by 14
Emerging biomarkers in chronic lung allograft dysfunction
Shtraichman, O., & Diamond, J. M. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1738929 · Cited by 13
Protective Effects of Thymoquinon on Pulmonary Disorders in Experimental Studies.
Noorbakhsh, M. F., Shaterzadeh‐Yazdi, H., Hayati, F., Samarghandian, S., & Farkhondeh, T. (2018) · PubMed Central · Cited by 14
Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis
Morizumi, S., Sato, S., Koyama, K., Okazaki, H., Chen, Y., Goto, H., Kagawa, K., Ogawa, H., Nishimura, H., Kawano, H., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0090oc · Cited by 15
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Brereton, C. J., & Jo, H. E. (2020) · Breathe · doi:10.1183/20734735.0086-2020 · Cited by 15
Dobashi, M., Tanaka, H., Taima, K., Itoga, M., Ishioka, Y., Shiratori, T., Okumura, F., Tabe, C., Tanaka, Y., Morimoto, T., et al. (2021) · SAGE Open Medicine · doi:10.1177/20503121211023357 · Cited by 14
Speca, S., Dubuquoy, C., Rousseaux, C., Chavatte, P., Desreumaux, P., & Spagnolo, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257281 · Cited by 13
Joannes, A., Morzadec, C., Duclos, M., Llamas‐Gutierrez, F., Chiforeanu, D. C., Naourès, C. L., Latour, B. R. D., Rouzé, S., Wollin, L., Jouneau, S., et al. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115972 · Cited by 13
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Wells, A. U. (2015) · European Respiratory Journal · doi:10.1183/09031936.00043915 · Cited by 14
Nishioka, Y., Homma, S., Ogura, T., Sato, S., Arai, N., Tomii, K., Kamio, K., Sakamoto, S., Miyazaki, Y., Tomioka, H., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.04.008 · Cited by 12
Self-citationHsia, I., Asmani, M., & Zhao, R. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115194 · Cited by 12
Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis
Zhao, T., & Su, Y. (2025) · Journal of Respiratory Biology and Translational Medicine · doi:10.70322/jrbtm.2025.10001 · Cited by 29
The PERK/ATF4 pathway is required for metabolic reprogramming and progressive lung fibrosis
Pandey, J., Larson‐Casey, J. L., Patil, M. H., He, C., Pinthong, N., & Carter, A. B. (2025) · JCI Insight · doi:10.1172/jci.insight.189330 · Cited by 17
Associations of interstitial lung disease subtype and CT pattern with lung function and survival
Kim, J. S., Pugashetti, J. V., Ma, S., Huang, Y., Podolanczuk, A. J., Lynch, D. A., Oh, A. S., Mychaleckyj, J. C., Manichaikul, A. W., Rich, S. S., et al. (2025) · Thorax · doi:10.1136/thorax-2024-222149 · Cited by 24
Self-citationOral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough
Molyneaux, P. L., Moğulkoç, N., Günen, H., Doboszyńska, A., Kreuter, M., Neustifter, B., Mathur, V. S., Cassella, J. V., CORAL Study Group, Bremner, P. R., et al. (2026) · JAMA · doi:10.1001/jama.2025.26179 · Cited by 12
Self-citationDigklia, A. (2014) · World Journal of Experimental Medicine · doi:10.5493/wjem.v4.i4.58 · Cited by 12
Adams, C. J., Shapera, S., Ryerson, C. J., Assayag, D., Johannson, K. A., Fell, C. D., Morisset, J., Manganas, H., Kolb, M. R. J., Hambly, N., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106722 · Cited by 11
Self-citationKlee, S., Picart‐Armada, S., Wenger, K., Birk, G., Quast, K., Veyel, D., Rist, W., Violet, C., Luippold, A. H., Haslinger, C., et al. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00253.2021 · Cited by 13
Targeting ATP12A, a Nongastric Proton Pump α Subunit, for Idiopathic Pulmonary Fibrosis Treatment
Abdelgied, M., Uhl, K. L., Chen, O. G., Schultz, C. R., Tripp, K., Peraino, A. M., Paithankar, S., Chen, B., Kakazu, M. T., Castillo-Bahena, A., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0264oc · Cited by 13
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis
Tomioka, H., Iwabayashi, M., Yokota, M., Hashimoto, R., & Amimoto, H. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102213 · Cited by 15
Çilli, A., Öcal, N., Üzer, F., Çoşkun, F., Sevinç, C., Ursavaş, A., Yildiz, P., Deniz, P. P., Demirci, N. Y., Ozbey, G., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.04.007 · Cited by 13
Nili, M., Epstein, A. J., Nunag, D., Olson, A. L., & Borah, B. J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02496-3 · Cited by 13
Kato, M., Sasaki, S., Mori, W., Kohmaru, M., Akimoto, T., Hayakawa, E., Soma, S., Arai, Y., Matsubara, N. S., Nakazawa, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39101-w · Cited by 13
Kizawa, R., Araya, J., & Fujita, Y. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00295-1 · Cited by 15
Targeted Therapy in Rheumatoid-Arthritis-Related Interstitial Lung Disease
Harrington, R., Harkins, P., & Conway, R. P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206657 · Cited by 20
Imperatorin ameliorates pulmonary fibrosis via GDF15 expression
Tsai, C., Chen, Y.-C., Li, Y., Wu, C.-T., Chang, P.-C., & Yeh, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1292137 · Cited by 11
Vitamin E stabilizes iron and mitochondrial metabolism in pulmonary fibrosis
Chang, J., Wang, J., Luo, B., Li, W., Xiong, Z., Du, C., Wang, X., Wang, Y., Tian, J., Li, S., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240829 · Cited by 12
Lettieri, S., Bertuccio, F. R., Frate, L. D., Perrotta, F., Corsico, A. G., & Stella, G. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010547 · Cited by 17
“No between-group difference was shown in terms of death for all causes [117].”
BackgroundNintedanib Plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis
Ikeda, S., Ogura, T., Kato, T., Kenmotsu, H., Agemi, Y., Tokito, T., Ito, K., Isomoto, K., Takiguchi, Y., Yoneshima, Y., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202311-941oc · Cited by 16
Interstitial Lung Disease Associated with Systemic Sclerosis
Mismetti, V., Si-Mohamed, S. A., & Cottin, V. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1786698 · Cited by 19
Self-citationLee, C. T., Hao, W., Burg, C., Best, J. H., Kolenic, G. E., & Strek, M. E. (2024) · Respiratory Research · doi:10.1186/s12931-024-02883-2 · Cited by 17
Choe, J., Hwang, H. J., Lee, S. M., Yoon, J., Kim, N., & Seo, J. B. (2024) · Investigative Radiology · doi:10.1097/rli.0000000000001103 · Cited by 16
Hoffmann, T., Teichgräber, U. K.-M., Förster, M., Oelzner, P., Kroegel, C., Renz, D. M., Weise, T., Böttcher, J., Schulze, P. C., Wolf, G., et al. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03371-0 · Cited by 13
Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?
Bączek, K., & Piotrowski, W. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1445923 · Cited by 12
Luppi, F., Manfredi, A., Faverio, P., Franco, G., Salvarani, C., Bendstrup, E. M., & Sebastiani, M. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103668 · Cited by 16
Emerging roles of noncoding RNAs in idiopathic pulmonary fibrosis
Wang, H., Sun, K., Peng, H. F., Wang, Y., & Zhang, L. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02170-5 · Cited by 17
Chaudhuri, N., Azuma, A., Sroka, K., Erhardt, E. M., Ritter, I., & Harari, S. A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03023-4 · Cited by 20
Self-citationLee, S., Kim, J.-H., Song, Y., Kim, S., Kang, H. J., Kim, J., Lee, Y., & Seo, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07522-2 · Cited by 13
Baratella, E., Borghesi, A., Calandriello, L., Cortese, G., Casa, G. D., Giraudo, C., Grassedonio, E., Larici, A. R., Palmucci, S., Romei, C., et al. (2025) · La radiologia medica · doi:10.1007/s11547-025-01985-1 · Cited by 13
Proteomic Biomarkers of Survival in Non–Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
Alqalyoobi, S., Smith, J. A., Maddali, M. V., Pugashetti, J. V., Newton, C. A., Kim, J. S., Linderholm, A., Chen, C., Ma, S., Bose, S., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202407-1506oc · Cited by 20
Provenzani, A., Vinci, D. L., Alaimo, M., Maria, S. D., Tuzzolino, F., Floridia, G., Stefano, R. D., Carollo, A., Callari, A., Polidori, P., et al. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251341645 · Cited by 16
Bundgaard-Nielsen, M., Johnsen, R. H., Mortensen, J., Shaker, S. B., & Nielsen, C. T. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103856 · Cited by 12
What if we made stratified medicine work for patients?
Britten, N., Pope, C. J., Halford, S., & Richeldi, L. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00499-3 · Cited by 13
Self-citationPharmacogenetics and interstitial lung disease
Oldham, J. M., Noth, I., & Martínez, F. J. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000289 · Cited by 12
Investigation of viral infection in idiopathic pulmonary fibrosis among Iranian patients in Tehran
Moradi, P., Keyvani, H., Mousavi, S.-A. J., Niya, M. H. K., Esghaei, M., Bokharaei‐Salim, F., Ataei‐Pirkooh, A., & Monavari, S. H. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.01.030 · Cited by 12
Idiopatic pulmonary fibrosis: A new paradigm
Avdeev, S. N. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017891112-122 · Cited by 13
A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
Kakuwa, T., Izumi, S., Sakamoto, K., et al. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.10.026 · Cited by 12
Guo, J., Hardie, W. D., Cleveland, Z. I., Davidson, C. R., Xu, X., Madala, S. K., & Woods, J. C. (2019) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00993.2018 · Cited by 12
Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials
Goldberg, H. J. (2019) · New England Journal of Medicine · doi:10.1056/nejme1911794 · Cited by 11
Refining the unilateral ureteral obstruction mouse model: No sham, no shame
Atkinson, J. M., Boden, T., Mocho, J.-P., et al. (2020) · Laboratory Animals · doi:10.1177/0023677220909401 · Cited by 12
“There are currently only two approved therapeutics for fibrosis (pirfenidone and nintedanib), and both are only approved for idiopathic pulmonary fibrosis.(2,3) There is therefore significant unmet medical need in fibrotic diseases of other organs, including the kidney.”
BackgroundAntifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
Hadda, V., & Guleria, R. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_90_20 · Cited by 14
Pintado‐Berninches, L., Montes‐Worboys, A., Manguán-García, C., Arias‐Salgado, E. G., Serrano, A., Fernández-Varas, B., Guerrero, R., Iarriccio, L., Planas‐Cerezales, L., Güenechea, G., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202001160rr · Cited by 13
Protective Effects of Extracellular Matrix-Derived Hydrogels in Idiopathic Pulmonary Fibrosis
Evangelista-Leite, D., Carreira, A. C. O., Gilpin, S. E., & Miglino, M. A. (2021) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0357 · Cited by 12
Choe, J., Kwon, B. S., Do, K., Hwang, H. S., Song, J. W., & Chae, E. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-95728-7 · Cited by 11
Nguyen, J., Armstrong, B. S., Cowman, S. J., Tomer, Y., Veerabhadraiah, S. R., Beers, M. F., & Venosa, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875887 · Cited by 13
“, PANTHER, ASCEND, INPULSIS, CleanUP) (Raghu et al., 2012; Richeldi et al., 2014; Martinez et al., 2021).”
An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis
Mateos‐Toledo, H., Mejía, M. E., Rodríguez-Barreto, Ó., Mejía-Hurtado, J. G., Rojas‐Serrano, J., Estrada, A., Castillo-Pedroza, J., Castillo-Castillo, K., Gaxiola, M., Buendía-Roldán, I., et al. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.08.008 · Cited by 12
Self-citationKeow, J. Y., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Respiratory Research · doi:10.1186/s12931-022-02067-w · Cited by 17
Nagy, T., Tóth, N. M., Palmer, E., Polivka, L., Csoma, B., Nagy, A., Eszes, N., Vincze, K., Bárczi, E., Bohács, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092129 · Cited by 14
Ebrahimpour, A., Ahir, M., Wang, M., Jegga, A. G., Bonnen, M., Eissa, N. T., Montesi, S. B., Raghu, G., & Ghebre, Y. T. (2022) · Scientific Reports · doi:10.1038/s41598-022-24985-x · Cited by 15
Self-citationPredictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study
Bernardinello, N., Cocconcelli, E., Giraudo, C., Daverio, M., Castelli, G., Petrarulo, S., Bovo, M., Fichera, G., Cavinato, S., Cattelan, A. M., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1084002 · Cited by 13
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.